The Clinical Characterization and Biorepository Core (CCBC) provides ORDRCC investigators with access to unique patient collections and new recruitment opportunities to aid their rheumatic disease research programs and to help facilitate their career development. This Core provides a centralized process for patient-oriented research training, patient/control identification and recruitment, and sample processing, as well as access to large collections of patient and control samples with associated clinical, demographic, therapeutic and disease activity measures. Based upon some recent changes in funding, the Clinical Characterization and Biorepository Core will encompass the previous ORDRCC Sample Procurement and Management Core (SPMC), along with samples and data from the historical Lupus Family Registry and Repository, to facilitate the clinical investigation of ORDRCC investigators and junior investigators. The OMRF SPMC was established with the funding of the ORDRCC, and has supported projects from 37 Junior ORDRCC Investigators (both from inside and outside Oklahoma, spanning from South Carolina to Alaska and from Chicago to California) and 19 ORDRCC Center Investigators. The goals of the Clinical Characterization and Biorepository Core are to: 1) Facilitate human subject recruitment, re-contact, consent and compliance. The CCBC ensures that human subject recruitment, clinical assessments and sample donation procedures meet rigorous standards of good clinical practice. By performing services in informed consent, regulatory reporting, oversight of the welfare of clinical study participants, and provision of expert clinical assessments using validated disease activity instruments, the CCBC supports and expands the research opportunities of all ORDRCC investigators. 2) Process and code samples provided to ORDRCC investigators. The CCBC ensures timely, protocol-driven processing, coding, storage and tracking of human biologic samples. 3) Provide samples and associated clinical data to ORDRCC research projects. Extensive clinical, demographic, disease activity and disease damage data exists on patients enrolled with systemic rheumatic diseases. The CCBC will make ORDRCC investigators aware of various patient and control clinical information and associated samples, which will be useful for their various projects. 4) Train ORDRCC junior investigators in human subject research. The ORDRCC helps ensure appropriate HIPAA and human subjects training of all ORDRCC personnel and training of personnel in use of the central OMRF Autoimmune Disease Institute data system.

Public Health Relevance

This CCB Core provides the resources necessary for all ORDRCC Investigators to access human clinical rheumatic disease information and samples to address their scientific needs. This centralized resource provides appropriate training and protection of human subjects, while also facilitating subject participation and provision of samples for a wide variety of rheumatic disease research questions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR053483-08
Application #
8734209
Study Section
Special Emphasis Panel (ZAR1-KM)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
8
Fiscal Year
2014
Total Cost
$202,359
Indirect Cost
$81,907
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Glauzy, Salomé; Boccitto, Marco; Bannock, Jason M et al. (2018) Accumulation of Antigen-Driven Lymphoproliferations in Complement Receptor 2/CD21-/low B Cells From Patients With Sjögren's Syndrome. Arthritis Rheumatol 70:298-307
St Clair, E William; Baer, Alan N; Wei, Chungwen et al. (2018) Clinical Efficacy and Safety of Baminercept, a Lymphotoxin ? Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol 70:1470-1480
Martínez-Bueno, Manuel; Oparina, Nina; Dozmorov, Mikhail G et al. (2018) Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks. Int J Mol Sci 19:
Koelsch, Kristi A; Cavett, Joshua; Smith, Kenneth et al. (2018) Evidence of Alternative Modes of B Cell Activation Involving Acquired Fab Regions of N-Glycosylation in Antibody-Secreting Cells Infiltrating the Labial Salivary Glands of Patients With Sjögren's Syndrome. Arthritis Rheumatol 70:1102-1113
LaBryer, Lauren; Sharma, Rohan; Chaudhari, Kaustubh Suresh et al. (2018) Kratom, an Emerging Drug of Abuse, Raises Prolactin and Causes Secondary Hypogonadism: Case Report. J Investig Med High Impact Case Rep 6:2324709618765022
Hinks, Anne; Marion, Miranda C; Cobb, Joanna et al. (2018) Brief Report: The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis. Arthritis Rheumatol 70:957-962
Karp, David R; Chong, Benjamin F; James, Judith A et al. (2018) Mock Recruitment for the Study of Antimalarials in Incomplete Lupus Erythematosus Trial. Arthritis Care Res (Hoboken) :
Pelikan, Richard C; Kelly, Jennifer A; Fu, Yao et al. (2018) Enhancer histone-QTLs are enriched on autoimmune risk haplotypes and influence gene expression within chromatin networks. Nat Commun 9:2905
Patel, Zubin; Lu, Xiaoming; Miller, Daniel et al. (2018) A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Hum Mol Genet :
Kheir, Joseph M; Guthridge, Carla J; Johnston, Jonathon R et al. (2018) Unique clinical characteristics, autoantibodies and medication use in Native American patients with systemic lupus erythematosus. Lupus Sci Med 5:e000247

Showing the most recent 10 out of 284 publications